Lotronex Review May Include Discussion Of Withdrawal Study, Patient Survey
Executive Summary
A randomized withdrawal study of GlaxoSmithKline's Lotronex would provide valuable information on the efficacy profile of the irritable bowel syndrome agent, FDA Office of Medical Policy Director Robert Temple, MD, suggested during the Food & Drug Law Institute's educational conference April 16 in Washington, D.C
You may also be interested in...
GSK Plans Lotronex Randomized Withdrawal Study If Drug Is Reintroduced
GlaxoSmithKline has committed to a randomized withdrawal study for Lotronex if the irritable bowel syndrome agent is allowed back onto the market
GSK Plans Lotronex Randomized Withdrawal Study If Drug Is Reintroduced
GlaxoSmithKline has committed to a randomized withdrawal study for Lotronex if the irritable bowel syndrome agent is allowed back onto the market
GSK Lotronex Limited-Access Program Revisited By FDA In Patient Letter
FDA is revisiting the dispute over a limited-access program for GlaxoSmithKline's withdrawn irritable bowel syndrome drugLotronex